{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:04:11Z","timestamp":1793325851395,"version":"4.5.0"},"reference-count":186,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Glioblastoma (GBM) tumors are the most aggressive primary brain tumors in adults that, despite maximum treatment, carry a dismal prognosis. GBM tumors exhibit tissue hypoxia, which promotes tumor aggressiveness and maintenance of glioma stem cells and creates an overall immunosuppressive landscape. This article reviews how hypoxic conditions overlap with inflammatory responses, favoring the proliferation of immunosuppressive cells and inhibiting cytotoxic T cell development. Immunotherapies, including vaccines, immune checkpoint inhibitors, and CAR-T cell therapy, represent promising avenues for GBM treatment. However, challenges such as tumor heterogeneity, immunosuppressive TME, and BBB restrictiveness hinder their effectiveness. Strategies to address these challenges, including combination therapies and targeting hypoxia, are actively being explored to improve outcomes for GBM patients. Targeting hypoxia in combination with immunotherapy represents a potential strategy to enhance treatment efficacy.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1384249","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:24:11Z","timestamp":1719361451000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":90,"title":["Hypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments"],"prefix":"10.3389","volume":"15","author":[{"given":"Lisa","family":"Feldman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"iii1","DOI":"10.1093\/neuonc\/noab200","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014\u20132018","volume":"23","author":"Ostrom","year":"2021","journal-title":"Neuro Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noaa200","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013\u20132017","volume":"22","author":"Ostrom","year":"2020","journal-title":"Neuro Oncol"},{"key":"B3","article-title":"\"Glioblastoma: Epidemiology and Outcome of Glioblastoma,\"","author":"Tamimi","year":"2017"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611977","article-title":"Short-course radiation plus temozolomide in elderly patients with glioblastoma","volume":"376","author":"Perry","year":"2017","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-019-0700-1","article-title":"A reignited debate over the cell(s) of origin for glioblastoma and its clinical implications","volume":"13","author":"Fan","year":"2019","journal-title":"Front Med"},{"key":"B6","unstructured":"Glioblastoma, IDH-wildtype\n            Gaillard FGJ\n            SharmaR\n          2008"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 world health organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/glia.v53:8","article-title":"Transplanted glioma cells migrate and proliferate on host brain vasculature: a dynamic analysis","volume":"53","author":"Farin","year":"2006","journal-title":"Glia"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/now086","article-title":"Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab","volume":"18","author":"Chang","year":"2016","journal-title":"Neuro Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu050","article-title":"High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","author":"Stupp","year":"2014","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005909127196","article-title":"Bone marrow metastasis in astrocytic gliomata","volume":"37","author":"Hsu","year":"1998","journal-title":"J Neurooncol"},{"key":"B12","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"key":"B13","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2015.12.028","article-title":"Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma","volume":"164","author":"Ceccarelli","year":"2016","journal-title":"Cell"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2246","article-title":"Making a tumour\u2019s bed: glioblastoma stem cells and the vascular niche","volume":"7","author":"Gilbertson","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1889","article-title":"Brain tumour stem cells","volume":"6","author":"Vescovi","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2015.10.009","article-title":"Glioblastoma: defining tumor niches","volume":"1","author":"Hambardzumyan","year":"2015","journal-title":"Trends Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1126\/science.1235122","article-title":"Cancer genome landscapes","volume":"339","author":"Vogelstein","year":"2013","journal-title":"Science"},{"key":"B18","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.cell.2012.01.021","article-title":"Hypoxia-inducible factors in physiology and medicine","volume":"148","author":"Semenza","year":"2012","journal-title":"Cell"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-3773","article-title":"Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with Malignant glioma","volume":"66","author":"Fecci","year":"2006","journal-title":"Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1846","article-title":"T-cell exhaustion signatures vary with tumor type and are severe in glioblastoma","volume":"24","author":"Woroniecka","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B21","doi-asserted-by":"crossref","DOI":"10.15586\/codon.glioblastoma.2017.ch16","article-title":"\"Glioblastoma: To Target the Tumor Cell or the Microenvironment","author":"De Vleeschouwer","year":"2017"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0135-2","article-title":"Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors","volume":"24","author":"Chongsathidkiet","year":"2018","journal-title":"Nat Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-008-0508-3","article-title":"Progression of intracranial glioma disrupts thymic homeostasis and induces T-cell apoptosis in vivo","volume":"57","author":"Andaloussi","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.770561","article-title":"Immunosuppression in glioblastoma: current understanding and therapeutic implications","volume":"11","author":"Himes","year":"2021","journal-title":"Front Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nou307","article-title":"Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma","volume":"17","author":"Berghoff","year":"2015","journal-title":"Neuro Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3892\/ol","article-title":"Profiling of inhibitory immune checkpoints in glioblastoma: Potential pathogenetic players","volume":"20","author":"Lombardo","year":"2020","journal-title":"Oncol Lett"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3171\/2008.7.JNS08475","article-title":"Flow cytometry and in vitro analysis of human glioma-associated macrophages. Laboratory investigation","volume":"110","author":"Parney","year":"2009","journal-title":"J Neurosurg"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2402","article-title":"Glioblastoma-derived IL6 induces immunosuppressive peripheral myeloid cell PD-L1 and promotes tumor growth","volume":"25","author":"Lamano","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1369","article-title":"Autologous heat shock protein peptide vaccination for newly diagnosed glioblastoma: impact of peripheral PD-L1 expression on response to therapy","volume":"23","author":"Bloch","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-03130-z","article-title":"PD1\/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression","volume":"71","author":"Filippone","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01605-y","article-title":"Kunitz-type protease inhibitor TFPI2 remodels stemness and immunosuppressive tumor microenvironment in glioblastoma","volume":"24","author":"Pang","year":"2023","journal-title":"Nat Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"101238","DOI":"10.1016\/j.xcrm.2023.101238","article-title":"Hypoxia-driven protease legumain promotes immunosuppression in glioblastoma","volume":"4","author":"Pang","year":"2023","journal-title":"Cell Rep Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1124\/pr.117.014647","article-title":"Neuroimmune axes of the blood-brain barriers and blood-brain interfaces: bases for physiological regulation, disease states, and pharmacological interventions","volume":"70","author":"Erickson","year":"2018","journal-title":"Pharmacol Rev"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.3390\/ijms24032111","article-title":"Natural killer cell-based immunotherapy against glioblastoma","volume":"24","author":"Morimoto","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2174\/1568026614666140329230311","article-title":"Recent advances in delivery through the blood-brain barrier","volume":"14","author":"Larsen","year":"2014","journal-title":"Curr Top Med Chem"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2012.07.004","article-title":"Capture, crawl, cross: the T cell code to breach the blood-brain barriers","volume":"33","author":"Engelhardt","year":"2012","journal-title":"Trends Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1593\/neo.11024","article-title":"B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory\/conditionally cytotoxic therapy for glioblastoma","volume":"13","author":"Candolfi","year":"2011","journal-title":"Neoplasia"},{"key":"B38","article-title":"Influence of the pro-inflammatory cytokines on P-glycoprotein expression and functionality","volume":"7","author":"Fernandez","year":"2004","journal-title":"J Pharm Pharm Sci"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.4.10.1245","article-title":"A critical overview of the influence of inflammation and infection on P-glycoprotein expression and activity in the brain","volume":"4","author":"Roberts","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.devcel.2007.01.013","article-title":"Endothelium-microenvironment interactions in the developing embryo and in the adult","volume":"12","author":"Red-Horse","year":"2007","journal-title":"Dev Cell"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2008.01.034","article-title":"HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion","volume":"13","author":"Du","year":"2008","journal-title":"Cancer Cell"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2013.02.021","article-title":"Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth","volume":"153","author":"Cheng","year":"2013","journal-title":"Cell"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/nature09624","article-title":"Glioblastoma stem-like cells give rise to tumour endothelium","volume":"468","author":"Wang","year":"2010","journal-title":"Nature"},{"key":"B44","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1042\/BC20110069","article-title":"Jumping the barrier: VE-cadherin, VEGF and other angiogenic modifiers in cancer","volume":"103","author":"Le Guelte","year":"2011","journal-title":"Biol Cell"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a020412","article-title":"The blood-brain barrier","volume":"7","author":"Daneman","year":"2015","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0400","article-title":"Circadian regulator CLOCK recruits immune-suppressive microglia into the GBM tumor microenvironment","volume":"10","author":"Chen","year":"2020","journal-title":"Cancer Discovery"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-21-0559","article-title":"Circadian regulator CLOCK drives immunosuppression in glioblastoma","volume":"10","author":"Xuan","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2021.06.008","article-title":"Circadian regulation of cancer cell and tumor microenvironment crosstalk","volume":"31","author":"Xuan","year":"2021","journal-title":"Trends Cell Biol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"112127","DOI":"10.1016\/j.celrep.2023.112127","article-title":"Circadian regulator CLOCK promotes tumor angiogenesis in glioblastoma","volume":"42","author":"Pang","year":"2023","journal-title":"Cell Rep"},{"key":"B50","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1023\/A:1015832726054","article-title":"Change of oxygen pressure in glioblastoma tissue under various conditions","volume":"58","author":"Beppu","year":"2002","journal-title":"J Neurooncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/now258","article-title":"Hypoxia in the glioblastoma microenvironment: shaping the phenotype of cancer stem-like cells","volume":"19","author":"Colwell","year":"2017","journal-title":"Neuro Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1320611111","article-title":"Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity","volume":"112","author":"Meyer","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1126\/science.1254257","article-title":"Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma","volume":"344","author":"Patel","year":"2014","journal-title":"Science"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/nature05236","article-title":"Glioma stem cells promote radioresistance by preferential activation of the DNA damage response","volume":"444","author":"Bao","year":"2006","journal-title":"Nature"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.252","article-title":"Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha","volume":"28","author":"Soeda","year":"2009","journal-title":"Oncogene"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.4161\/cc.6.4.3856","article-title":"N-CoR pathway targeting induces glioblastoma derived cancer stem cell differentiation","volume":"6","author":"Park","year":"2007","journal-title":"Cell Cycle"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2714","article-title":"Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen","volume":"14","author":"Doedens","year":"2013","journal-title":"Nat Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2730","article-title":"Immunobiological characterization of cancer stem cells isolated from glioblastoma patients","volume":"16","author":"Di Tomaso","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.2014.964211","article-title":"NF-kappaB and STAT3 in glioblastoma: therapeutic targets coming of age","volume":"14","author":"Gray","year":"2014","journal-title":"Expert Rev Neurother"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/nri2607","article-title":"Interdependence of hypoxic and innate immune responses","volume":"9","author":"Nizet","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.hoc.2018.12.001","article-title":"Cancer vaccines","volume":"33","author":"DeMaria","year":"2019","journal-title":"Hematol Oncol Clin North Am"},{"key":"B62","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41541-019-0103-y","article-title":"Turning the corner on therapeutic cancer vaccines","volume":"4","author":"Hollingsworth","year":"2019","journal-title":"NPJ Vaccines"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.817296","article-title":"CAR T cell therapy in primary brain tumors: current investigations and the future","volume":"13","author":"Lin","year":"2022","journal-title":"Front Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.3.2.14239","article-title":"Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier","volume":"3","author":"Lampson","year":"2011","journal-title":"MAbs"},{"key":"B65","doi-asserted-by":"publisher","first-page":"108193","DOI":"10.1016\/j.pharmthera.2022.108193","article-title":"Clinical advances in oncolytic virotherapy for pediatric brain tumors","volume":"239","author":"Ghajar-Rahimi","year":"2022","journal-title":"Pharmacol Ther"},{"key":"B66","doi-asserted-by":"publisher","first-page":"146217","DOI":"10.1016\/j.gene.2022.146217","article-title":"Gospel of Malignant Glioma: Oncolytic virus therapy","volume":"818","author":"Li","year":"2022","journal-title":"Gene"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.679425","article-title":"Immune checkpoint inhibitors in human glioma microenvironment","volume":"12","author":"Ghouzlani","year":"2021","journal-title":"Front Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002890corr1","article-title":"Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors","volume":"9","author":"Guidon","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.17.8078","article-title":"Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells","volume":"92","author":"Mukherji","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2016-0059","article-title":"Novel vaccines for glioblastoma: clinical update and perspective","volume":"8","author":"Winograd","year":"2016","journal-title":"Immunotherapy"},{"key":"B71","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(17)30517-X","article-title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.21037\/tcr","article-title":"Lessons learned from rindopepimut treatment in patients with EGFRvIII-expressing glioblastoma","volume":"7","author":"Binder","year":"2018","journal-title":"Transl Cancer Res"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/not203","article-title":"Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial","volume":"16","author":"Bloch","year":"2014","journal-title":"Neuro Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.12.149","article-title":"Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System","volume":"22","author":"Barnholtz-Sloan","year":"2004","journal-title":"J Clin Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10541","article-title":"Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma","volume":"94","author":"Schouten","year":"2002","journal-title":"Cancer"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nox077","article-title":"Incidence and prognosis of patients with brain metastases at diagnosis of systemic Malignancy: a population-based study","volume":"19","author":"Cagney","year":"2017","journal-title":"Neuro Oncol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3390\/cancers12030586","article-title":"The current status of immune checkpoint inhibitors in neuro-oncology: A systematic review","volume":"12","author":"Brahm","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the checkMate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"vdac025","DOI":"10.1093\/noajnl\/vdac025","article-title":"Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143","volume":"4","author":"Omuro","year":"2022","journal-title":"Neurooncol Adv"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac116","article-title":"Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter","volume":"24","author":"Lim","year":"2022","journal-title":"Neuro Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.662064","article-title":"CAR T cell-based immunotherapy for the treatment of glioblastoma","volume":"15","author":"Maggs","year":"2021","journal-title":"Front Neurosci"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nou045","article-title":"Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy","volume":"16","author":"Thaci","year":"2014","journal-title":"Neuro Oncol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nov280","article-title":"CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients","volume":"18","author":"Dubinski","year":"2016","journal-title":"Neuro Oncol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0077769","article-title":"Glioma IL13Ralpha2 is associated with mesenchymal signature gene expression and poor patient prognosis","volume":"8","author":"Brown","year":"2013","journal-title":"PloS One"},{"key":"B85","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"B87","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aar2766","article-title":"Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles","volume":"4","author":"Ricklefs","year":"2018","journal-title":"Sci Adv"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1007\/s004010100448","article-title":"Cytokine and cytokine receptor mRNA expression in human glioblastomas: evidence of Th1, Th2 and Th3 cytokine dysregulation","volume":"103","author":"Hao","year":"2002","journal-title":"Acta Neuropathol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1625","article-title":"Immunotherapy for glioblastoma: adoptive T-cell strategies","volume":"25","author":"Choi","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1215\/15228517-2006-008","article-title":"The role of human glioma-infiltrating microglia\/macrophages in mediating antitumor immune responses","volume":"8","author":"Hussain","year":"2006","journal-title":"Neuro Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v14.i4.138","article-title":"Immunotherapy in glioblastoma treatment: Current state and future prospects","volume":"14","author":"Rocha Pinheiro","year":"2023","journal-title":"World J Clin Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb2311","article-title":"Immunocytokines are a promising immunotherapeutic approach against glioblastoma","volume":"12","author":"Weiss","year":"2020","journal-title":"Sci Transl Med"},{"key":"B95","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/s41467-020-20599-x","article-title":"Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma","volume":"12","author":"Agliardi","year":"2021","journal-title":"Nat Commun"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2008.62","article-title":"TNF-alpha and the IFN-gamma-inducible protein 10 (IP-10\/CXCL-10) delivered by parvoviral vectors act in synergy to induce antitumor effects in mouse glioblastoma","volume":"16","author":"Enderlin","year":"2009","journal-title":"Cancer Gene Ther"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.8.1328","article-title":"A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients","volume":"6","author":"Feinberg","year":"1988","journal-title":"J Clin Oncol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190347","article-title":"Historical overview of the interleukin-6 family cytokine","volume":"217","author":"Kang","year":"2020","journal-title":"J Exp Med"},{"key":"B99","doi-asserted-by":"publisher","first-page":"a028415","DOI":"10.1101\/cshperspect.a028415","article-title":"Interleukin-6 family cytokines","volume":"10","author":"Rose-John","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1089\/jir.2023.0103","article-title":"Interleukin-6 family of cytokines in cancers","volume":"44","author":"Zaporowska-Stachowiak","year":"2024","journal-title":"J Interferon Cytokine Res"},{"key":"B101","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41467-018-03050-0","article-title":"Vascular niche IL-6 induces alternative macrophage activation in glioblastoma through HIF-2alpha","volume":"9","author":"Wang","year":"2018","journal-title":"Nat Commun"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2004.11.017","article-title":"Prognostic and clinical implication of IL-6 expression in glioblastoma multiforme","volume":"12","author":"Chang","year":"2005","journal-title":"J Clin Neurosci"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2019.07.020","article-title":"Tumor-associated macrophage related interleukin-6 in cerebrospinal fluid as a prognostic marker for glioblastoma","volume":"68","author":"Hori","year":"2019","journal-title":"J Clin Neurosci"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.v7i27","article-title":"Musashi-1 regulates AKT-derived IL-6 autocrinal\/paracrinal Malignancy and chemoresistance in glioblastoma","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"key":"B105","article-title":"IL-8 and IL-6 bystander signalling in human glioblastoma cells exposed to gamma radiation","volume":"30","author":"Pasi","year":"2010","journal-title":"Anticancer Res"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3892\/or","article-title":"IL-6 augments the invasiveness of U87MG human glioblastoma multiforme cells via up-regulation of MMP-2 and fascin-1","volume":"23","author":"Li","year":"2010","journal-title":"Oncol Rep"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.944452","article-title":"Advances in immunotherapy for glioblastoma multiforme","volume":"13","author":"Mahmoud","year":"2022","journal-title":"Front Immunol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-017-0516-0","article-title":"Oncolytic virotherapy for the treatment of Malignant glioma","volume":"14","author":"Foreman","year":"2017","journal-title":"Neurotherapeutics"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0077-0","article-title":"Viruses in cancer therapy - from benchwarmers to quarterbacks","volume":"15","author":"Peruzzi","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1002\/mef2.61","article-title":"Oncolytic viral therapy as promising immunotherapy against glioma","volume":"2","author":"Hu","year":"2023","journal-title":"MedComm \u2013 Future Med"},{"key":"B111","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B112","doi-asserted-by":"publisher","first-page":"547","DOI":"10.3390\/v15020547","article-title":"Recent developments in glioblastoma therapy: oncolytic viruses and emerging future strategies","volume":"15","author":"Hamad","year":"2023","journal-title":"Viruses"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-017-0520-4","article-title":"Convection-enhanced delivery","volume":"14","author":"Mehta","year":"2017","journal-title":"Neurotherapeutics"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.23.1790","article-title":"In vivo antitumor activity of Sindbis viral vectors","volume":"94","author":"Tseng","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111658200","article-title":"Infection of glioma cells with Sindbis virus induces selective activation and tyrosine phosphorylation of protein kinase C delta. Implications for Sindbis virus-induced apoptosis","volume":"277","author":"Zrachia","year":"2002","journal-title":"J Biol Chem"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0925","article-title":"Safe and effective treatment of experimental neuroblastoma and glioblastoma using systemically delivered triple microRNA-detargeted oncolytic semliki forest virus","volume":"23","author":"Ramachandran","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/not065","article-title":"Intravenous injection of oncolytic picornavirus SVV-001 prolongs animal survival in a panel of primary tumor-based orthotopic xenograft mouse models of pediatric glioma","volume":"15","author":"Liu","year":"2013","journal-title":"Neuro Oncol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1093\/neuros\/nyy047","article-title":"Zika virus has oncolytic activity against glioblastoma stem cells","volume":"82","author":"Lubin","year":"2018","journal-title":"Neurosurgery"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-018-1240-4","article-title":"CD73 downregulation decreases in vitro and in vivo glioblastoma growth","volume":"56","author":"Azambuja","year":"2019","journal-title":"Mol Neurobiol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41591-019-0694-x","article-title":"Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma","volume":"26","author":"Goswami","year":"2020","journal-title":"Nat Med"},{"key":"B121","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ccell.2017.07.006","article-title":"Macrophage polarization contributes to glioblastoma eradication by combination immunovirotherapy and immune checkpoint blockade","volume":"32","author":"Saha","year":"2017","journal-title":"Cancer Cell"},{"key":"B122","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1016\/j.cell.2022.09.015","article-title":"A pan-cancer mycobiome analysis reveals fungal involvement in gastrointestinal and lung tumors","volume":"185","author":"Dohlman","year":"2022","journal-title":"Cell"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.09.013","article-title":"The tumor mycobiome: A paradigm shift in cancer pathogenesis","volume":"185","author":"Li","year":"2022","journal-title":"Cell"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1301506","article-title":"Intratumoral microbiota: implications for cancer onset, progression, and therapy","volume":"14","author":"Wu","year":"2023","journal-title":"Front Immunol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202301679","article-title":"Discovery of intratumoral oncolytic bacteria toward targeted anticancer theranostics","volume":"10","author":"Goto","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1126\/science.abp9563","article-title":"Engineered skin bacteria induce antitumor T cell responses against melanoma","volume":"380","author":"Chen","year":"2023","journal-title":"Science"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06081-w","article-title":"Microbial peptides activate tumour-infiltrating lymphocytes in glioblastoma","volume":"617","author":"Naghavian","year":"2023","journal-title":"Nature"},{"key":"B128","doi-asserted-by":"publisher","first-page":"1877416","DOI":"10.1080\/2162402X.2021.1877416","article-title":"Cross-reactivity between cancer and microbial antigens","volume":"10","author":"Zitvogel","year":"2021","journal-title":"Oncoimmunology"},{"key":"B129","doi-asserted-by":"crossref","DOI":"10.1126\/science.aay9189","article-title":"The human tumor microbiome is composed of tumor type-specific intracellular bacteria","volume":"368","author":"Nejman","year":"2020","journal-title":"Science"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"B131","doi-asserted-by":"publisher","first-page":"104963","DOI":"10.1016\/j.ebiom.2023.104963","article-title":"Glioblastoma vaccines: past, present, and opportunities","volume":"100","author":"Xiong","year":"2024","journal-title":"EBioMedicine"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02361-4","article-title":"Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities","volume":"129","author":"Wang","year":"2023","journal-title":"Br J Cancer"},{"key":"B133","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/ijms19103044","article-title":"Role of hypoxic stress in regulating tumor immunogenicity, resistance and plasticity","volume":"19","author":"Terry","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.79","article-title":"Hypoxia-activated prodrugs: paths forward in the era of personalised medicine","volume":"114","author":"Hunter","year":"2016","journal-title":"Br J Cancer"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(94)90293-3","article-title":"Muscle cramping in phase I clinical trials of tirapazamine (SR 4233) with and without radiation","volume":"29","author":"Doherty","year":"1994","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B136","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1517\/13543780802567250","article-title":"Tirapazamine: a novel agent targeting hypoxic tumor cells","volume":"18","author":"Reddy","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2011.11.101","article-title":"Phase 2 study of adjuvant intravesical instillations of apaziquone for high risk nonmuscle invasive bladder cancer","volume":"187","author":"Hendricksen","year":"2012","journal-title":"J Urol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj306","article-title":"Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs","volume":"98","author":"Hicks","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"B139","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.3390\/cells8091083","article-title":"Improving cancer immunotherapy by targeting the hypoxic tumor microenvironment: new opportunities and challenges","volume":"8","author":"Noman","year":"2019","journal-title":"Cells"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1172\/JCI96268","article-title":"Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy","volume":"128","author":"Jayaprakash","year":"2018","journal-title":"J Clin Invest"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4118","article-title":"A phase I dose-escalation study to evaluate the safety and tolerability of evofosfamide in combination with ipilimumab in advanced solid Malignancies","volume":"27","author":"Hegde","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.3660","article-title":"Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma","volume":"32","author":"Chawla","year":"2014","journal-title":"J Clin Oncol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30381-9","article-title":"Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406\/SARC021): an international, multicentre, open-label, randomised phase 3 trial","volume":"18","author":"Tap","year":"2017","journal-title":"Lancet Oncol"},{"key":"B144","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1038\/s41598-021-81841-0","article-title":"Phase 2 trial of hypoxia activated evofosfamide (TH302) for treatment of recurrent bevacizumab-refractory glioblastoma","volume":"11","author":"Brenner","year":"2021","journal-title":"Sci Rep"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1002\/med.21477","article-title":"Hypoxia-inducible factor-1 (HIF-1) inhibitors from the last decade (2007 to 2016): A \u201cstructure-activity relationship\u201d perspective","volume":"38","author":"Bhattarai","year":"2018","journal-title":"Med Res Rev"},{"key":"B146","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40883-019-00113-6","article-title":"Strategies for targeting cancer immunotherapy through modulation of the tumor microenvironment","volume":"6","author":"Parayath","year":"2020","journal-title":"Regenerative Eng Trans Med"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3301388","article-title":"Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy","volume":"8","author":"Sun","year":"2001","journal-title":"Gene Ther"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1879-5","article-title":"Inhibition of HIF-1alpha enhances anti-tumor effects of dendritic cell-based vaccination in a mouse model of breast cancer","volume":"65","author":"Kheshtchin","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"B149","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/hep.28655","article-title":"Hypoxia induces myeloid-derived suppressor cell recruitment to hepatocellular carcinoma through chemokine (C-C motif) ligand 26","volume":"64","author":"Chiu","year":"2016","journal-title":"Hepatology"},{"key":"B150","article-title":"Spotlight on 17-AAG as an Hsp90 inhibitor for molecular targeted cancer treatment","volume":"93","author":"Mellatyar","year":"2019","journal-title":"Chem Biol Drug Des"},{"key":"B151","doi-asserted-by":"publisher","first-page":"BSR20211056","DOI":"10.1042\/BSR20211056","article-title":"Digoxin exerts anticancer activity on human nonsmall cell lung cancer cells by blocking PI3K\/Akt pathway","volume":"41","author":"Wang","year":"2021","journal-title":"Biosci Rep"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(03)00077-1","article-title":"2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF","volume":"3","author":"Mabjeesh","year":"2003","journal-title":"Cancer Cell"},{"key":"B153","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1146\/annurev-pharmtox-010818-021637","article-title":"Pharmacologic targeting of hypoxia-inducible factors","volume":"59","author":"Semenza","year":"2019","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2016.04.009","article-title":"Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer","volume":"164","author":"Wigerup","year":"2016","journal-title":"Pharmacol Ther"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.2627","article-title":"Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2alpha antagonist in patients with previously treated advanced clear cell renal cell carcinoma","volume":"36","author":"Courtney","year":"2018","journal-title":"J Clin Oncol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-023-04456-7","article-title":"Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma","volume":"165","author":"Strowd","year":"2023","journal-title":"J Neurooncol"},{"key":"B157","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.3390\/biom11111604","article-title":"Targeting hypoxia: revival of old remedies","volume":"11","author":"Vilaplana-Lopera","year":"2021","journal-title":"Biomolecules"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS5094","article-title":"Phase III study of the hypoxia-inducible factor 2\u03b1 (HIF-2\u03b1) inhibitor MK-6482 versus everolimus in previously treated patients with advanced clear cell renal cell carcinoma (ccRCC)","volume":"38","author":"Choueiri","year":"2020","journal-title":"J Clin Oncol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38415.708634.F7","article-title":"Metformin and reduced risk of cancer in diabetic patients","volume":"330","author":"Evans","year":"2005","journal-title":"BMJ"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2015.06.003","article-title":"Metformin: A novel biological modifier of tumor response to radiation therapy","volume":"93","author":"Koritzinsky","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1787","article-title":"Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response","volume":"19","author":"Zannella","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.2318","article-title":"Addition of metformin to concurrent chemoradiation in patients with locally advanced non-small cell lung cancer: the NRG-LU001 phase 2 randomized clinical trial","volume":"7","author":"Skinner","year":"2021","journal-title":"JAMA Oncol"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.2328","article-title":"Metformin in combination with chemoradiotherapy in locally advanced non-small cell lung cancer: the OCOG-ALMERA randomized clinical trial","volume":"7","author":"Tsakiridis","year":"2021","journal-title":"JAMA Oncol"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02204-2","article-title":"Is it still worth pursuing the repurposing of metformin as a cancer therapeutic","volume":"128","author":"Lord","year":"2023","journal-title":"Br J Cancer"},{"key":"B165","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.canlet.2020.05.011","article-title":"The hypoxic tumour microenvironment: A safe haven for immunosuppressive cells and a therapeutic barrier to overcome","volume":"487","author":"Chang","year":"2020","journal-title":"Cancer Lett"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0657","article-title":"Targeting hypoxia-induced carbonic anhydrase IX enhances immune-checkpoint blockade locally and systemically","volume":"7","author":"Chafe","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B167","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.3390\/cancers14061392","article-title":"Carbonic anhydrase IX: A renewed target for cancer immunotherapy","volume":"14","author":"Campos","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B168","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13046-020-01820-7","article-title":"Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy","volume":"40","author":"Wang","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.826","article-title":"Role of adenosine A2a receptor in cancers and autoimmune diseases","volume":"11","author":"Ye","year":"2023","journal-title":"Immun Inflammation Dis"},{"key":"B170","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12943-017-0665-0","article-title":"Blockade of adenosine A2A receptor enhances CD8(+) T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma","volume":"16","author":"Ma","year":"2017","journal-title":"Mol Cancer"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1172\/JCI89455","article-title":"Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy","volume":"127","author":"Beavis","year":"2017","journal-title":"J Clin Invest"},{"key":"B172","doi-asserted-by":"publisher","first-page":"118389","DOI":"10.1016\/j.lfs.2020.118389","article-title":"Ectonucleotidase CD73 and CD39 expression in non-small cell lung cancer relates to hypoxia and immunosuppressive pathways","volume":"259","author":"Giatromanolaki","year":"2020","journal-title":"Life Sci"},{"key":"B173","doi-asserted-by":"publisher","first-page":"112886","DOI":"10.1016\/j.yexcr.2021.112886","article-title":"Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo","volume":"409","author":"Liu","year":"2021","journal-title":"Exp Cell Res"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1172\/JCI128895","article-title":"CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment","volume":"130","author":"Neo","year":"2020","journal-title":"J Clin Invest"},{"key":"B175","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1038\/s41467-024-46193-z","article-title":"Lactate dehydrogenase A regulates tumor-macrophage symbiosis to promote glioblastoma progression","volume":"15","author":"Khan","year":"2024","journal-title":"Nat Commun"},{"key":"B176","doi-asserted-by":"publisher","first-page":"rs.3.rs-3401154","DOI":"10.21203\/rs.3.rs-3401154\/v1","article-title":"LDHA-regulated tumor-macrophage symbiosis promotes glioblastoma progression","volume":"5","author":"Khan","year":"2023","journal-title":"Res Sq"},{"key":"B177","doi-asserted-by":"publisher","first-page":"277ra30","DOI":"10.1126\/scitranslmed.aaa1260","article-title":"Immunological mechanisms of the antitumor effects of supplemental oxygenation","volume":"7","author":"Hatfield","year":"2015","journal-title":"Sci Transl Med"},{"key":"B178","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1158\/2326-6066.CIR-16-0103","article-title":"Efficacy of PD-1 blockade is potentiated by metformin-induced reduction of tumor hypoxia","volume":"5","author":"Scharping","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B179","doi-asserted-by":"publisher","first-page":"CD005007","DOI":"10.1002\/14651858.CD005007.pub4","article-title":"Hyperbaric oxygenation for tumour sensitisation to radiotherapy","volume":"4","author":"Bennett","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1993.326","article-title":"Further evaluation of nicotinamide and carbogen as a strategy to reoxygenate hypoxic cells in vivo: importance of nicotinamide dose and pre-irradiation breathing time","volume":"68","author":"Chaplin","year":"1993","journal-title":"Br J Cancer"},{"key":"B181","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.21057","article-title":"Concurrent carbogen and radiation therapy in children with high-risk brainstem gliomas","volume":"50","author":"Aquino-Parsons","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00221","article-title":"Resistance mechanisms to anti-angiogenic therapies in cancer","volume":"10","author":"Haibe","year":"2020","journal-title":"Front Oncol"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0053","article-title":"Bevacizumab plus ipilimumab in patients with metastatic melanoma","volume":"2","author":"Hodi","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B184","doi-asserted-by":"publisher","first-page":"12624","DOI":"10.1038\/ncomms12624","article-title":"Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma","volume":"7","author":"Wallin","year":"2016","journal-title":"Nat Commun"},{"key":"B185","doi-asserted-by":"publisher","first-page":"111607","DOI":"10.1016\/j.biopha.2021.111607","article-title":"Vascular normalization in immunotherapy: A promising mechanisms combined with radiotherapy","volume":"139","author":"Liu","year":"2021","journal-title":"BioMed Pharmacother"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaw7875","article-title":"Vascular regulation of antitumor immunity","volume":"365","author":"Munn","year":"2019","journal-title":"Science"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1384249\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:24:20Z","timestamp":1719361460000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1384249\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,26]]},"references-count":186,"alternative-id":["10.3389\/fimmu.2024.1384249"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1384249","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,26]]},"article-number":"1384249"}}